The Federal Trade Commission (FTC), an agency traditionally tasked with preventing fraud and protecting consumer rights, is undergoing a significant shift in focus. Recent actions suggest the agency is pivoting to frame gender-affirming care for minors as a matter of “deceptive practices,” a move that experts and former employees warn could fundamentally alter the landscape of transgender healthcare in the United States.
A Shift in Investigative Strategy
Since mid-2025, the FTC has moved beyond its usual scope of policing fake products and financial scams. Instead, the Bureau of Consumer Protection has begun issuing Civil Investigative Demands (CIDs) —legal instruments similar to subpoenas—to major medical nonprofits.
Targeted organizations include:
– The American Academy of Pediatrics
– The World Professional Association for Transgender Health (WPATH)
– The Endocrine Society
By targeting these “standard-setters,” the FTC is not just investigating individual doctors; it is scrutinizing the very organizations that establish medical protocols for transgender healthcare. Legal experts suggest this strategy may be an attempt to frame the entire field of transgender medicine as inherently deceptive.
New Leadership and Specialized Hiring
The agency’s direction appears to be driven by a deliberate restructuring of its personnel. Two key developments highlight this trend:
- Specialized Legal Recruitment: The FTC has recently posted high-level job openings for lawyers specifically tasked with investigating “unfair and deceptive practices” related to pediatric gender dysphoria treatment.
- Key Appointments: The agency has brought on Glenna Goldis as the Assistant Director for Special Projects (Children and Adolescents). Goldis, a former New York state official, has publicly expressed intentions to target the medical licenses and professional standing of providers who offer gender-affirming care.
The High Cost of Compliance
For the medical nonprofits under investigation, the burden is both financial and operational. Mila Becker, Chief Policy Officer at the Endocrine Society, noted that responding to these demands could cost her organization over $500,000, in addition to massive amounts of staff time.
Beyond the money, there are significant legal and ethical hurdles:
* Privacy Concerns: Investigating these groups requires navigating sensitive, anonymized patient data and third-party privacy interests.
* The “Chilling Effect”: Experts worry that if the FTC aggressively pursues nonprofits, for-profit medical groups will follow suit. This could lead doctors to quietly cease providing transgender healthcare to avoid legal and financial ruin.
Context: A Broader Political Agenda
This FTC pivot does not exist in a vacuum. It is part of a broader administrative push to dismantle transgender rights through federal policy. FTC Chair Andrew Ferguson has been vocal about his mission to fight the “trans agenda,” alleging that providers “deceptively” push medical interventions on patients without disclosing risks.
“The FTC has brought lots of cases around phony cures… but these cases are targeting nonprofits outside its traditional jurisdiction,” warns one former FTC employee.
This shift aligns with recent executive orders aimed at “restoring biological truth” to the federal government, signaling a move to use regulatory agencies as tools for social and medical policy enforcement.
Conclusion
By reframing medical protocols as consumer deception, the FTC is moving into a controversial new role that threatens the financial stability of medical nonprofits and the availability of gender-affirming care. This shift marks a significant escalation in the use of federal regulatory power to influence healthcare standards.
